Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel
NASDAQ:PRLD

Prelude Therapeutics Q3 2026 Earnings Date & Estimates

Prelude Therapeutics logo
$3.32 +0.09 (+2.79%)
Closing price 04:00 PM Eastern
Extended Trading
$3.32 0.00 (0.00%)
As of 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Prelude Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Prelude Therapeutics in Q3 2026

Prelude Therapeutics is expected to post earnings of $0.0040 per share on revenue of $29.00 million. In the same quarter a year earlier Prelude Therapeutics reported -$0.26 per share on revenue of $6.50 million. Prelude Therapeutics last reported on August 11, 2026, posting -$0.14 per share and beating the -$0.1967 consensus estimate. Prelude Therapeutics has beaten the consensus EPS estimate in 8 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.0040
Expected Revenue
$29.00 million
Prior-Year EPS
-$0.26
Prior-Year Revenue
$6.50 million
Expected Revenue Growth
+346.2%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.14 (Beat by +$0.0567)
Last Quarter Revenue
$5.70 million
EPS Beat Rate
8 of last 8 quarters

Prepare for the Q3 2026 Call

Prelude Therapeutics Q3 2026 Earnings FAQ

Prelude Therapeutics (NASDAQ:PRLD) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Prelude Therapeutics' Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Prelude Therapeutics to post earnings of $0.0040 per share for Q3 2026.

The consensus revenue estimate for Prelude Therapeutics is $29.00 million for Q3 2026.

Prelude Therapeutics Earnings Headlines

Prelude Therapeutics Incorporated Proceeds With Phase 1 Study Of PRT13722 In Patients With HR+/HER2- Breast Cancer
October 14 at 7:49 PM  |  marketscreener.comM
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in ...
October 13 at 8:59 AM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/prelude-announces-clinical-trial-collaboration-and-supply-agreement-with-lilly-to-evaluate-kat6a-selective-degrader-prt13722-in-combination-with-verzenio-and-inluriyo-in-patients-with-hr-her2--1036620238
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
October 15 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Prelude, Lilly Partner On Breast Cancer Combination Trial; Stock Up
October 13 at 8:59 AM  |  rttnews.comhttps://www.rttnews.com/3698518/prelude-lilly-partner-on-breast-cancer-combination-trial-stock-up.aspx
Prelude Therapeutics, Eli Lilly to Study Breast Cancer Drug Combinations in Phase 1 Trial
October 13 at 8:59 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/prelude-therapeutics-eli-lilly-study-113910214.html
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
October 13 at 7:01 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/13/3379542/0/en/prelude-announces-clinical-trial-collaboration-and-supply-agreement-with-lilly-to-evaluate-kat6a-selective-degrader-prt13722-in-combination-with-verzenio-and-inluriyo-in-patients-w.html
See More Prelude Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prelude Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prelude Therapeutics and other key companies, straight to your email.

About Prelude Therapeutics

Prelude Therapeutics (NASDAQ:PRLD) Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company uses cancer biology, medicinal chemistry and targeted drug-discovery approaches to identify small-molecule therapies designed to address genetic and molecular vulnerabilities in tumors.

Prelude’s investigational pipeline has included PRT3789, a selective SMARCA2 protein degrader being developed for cancers with SMARCA4 loss, and PRT2527, a selective cyclin-dependent kinase 9 (CDK9) inhibitor under evaluation for oncology applications. These programs are investigational and are not approved for commercial use.

Founded in 2016 and headquartered in Wilmington, Delaware, Prelude conducts research and clinical development activities in the United States. The company was founded by David Mack, Ph.D., who has served as its president and chief executive officer. As a clinical-stage biotechnology company, Prelude’s operations are primarily focused on advancing its drug candidates through clinical testing and establishing potential treatment options for patients with cancer.

View Prelude Therapeutics Profile
Earnings Tools